1. Home
  2. TVTX vs DMLP Comparison

TVTX vs DMLP Comparison

Compare TVTX & DMLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVTX
  • DMLP
  • Stock Information
  • Founded
  • TVTX 2008
  • DMLP 2003
  • Country
  • TVTX United States
  • DMLP United States
  • Employees
  • TVTX N/A
  • DMLP 27
  • Industry
  • TVTX Biotechnology: Pharmaceutical Preparations
  • DMLP Oil & Gas Production
  • Sector
  • TVTX Health Care
  • DMLP Energy
  • Exchange
  • TVTX Nasdaq
  • DMLP Nasdaq
  • Market Cap
  • TVTX 1.5B
  • DMLP 1.2B
  • IPO Year
  • TVTX N/A
  • DMLP N/A
  • Fundamental
  • Price
  • TVTX $23.36
  • DMLP $25.48
  • Analyst Decision
  • TVTX Strong Buy
  • DMLP
  • Analyst Count
  • TVTX 16
  • DMLP 0
  • Target Price
  • TVTX $35.07
  • DMLP N/A
  • AVG Volume (30 Days)
  • TVTX 2.6M
  • DMLP 108.7K
  • Earning Date
  • TVTX 10-30-2025
  • DMLP 10-30-2025
  • Dividend Yield
  • TVTX N/A
  • DMLP 12.62%
  • EPS Growth
  • TVTX N/A
  • DMLP N/A
  • EPS
  • TVTX N/A
  • DMLP 1.71
  • Revenue
  • TVTX $333,865,000.00
  • DMLP $161,859,000.00
  • Revenue This Year
  • TVTX $83.26
  • DMLP N/A
  • Revenue Next Year
  • TVTX $43.19
  • DMLP N/A
  • P/E Ratio
  • TVTX N/A
  • DMLP $14.83
  • Revenue Growth
  • TVTX 87.94
  • DMLP 4.04
  • 52 Week Low
  • TVTX $11.89
  • DMLP $24.01
  • 52 Week High
  • TVTX $28.69
  • DMLP $34.88
  • Technical
  • Relative Strength Index (RSI)
  • TVTX 64.87
  • DMLP 52.88
  • Support Level
  • TVTX $20.84
  • DMLP $24.50
  • Resistance Level
  • TVTX $28.69
  • DMLP $25.60
  • Average True Range (ATR)
  • TVTX 1.44
  • DMLP 0.46
  • MACD
  • TVTX 0.62
  • DMLP 0.17
  • Stochastic Oscillator
  • TVTX 56.60
  • DMLP 92.83

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests

Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.

Share on Social Networks: